Data reported from the TAILORx, MINDACT, and RxPONDER trials showed that premenopausal or younger (≤50 years) women, with HR+HER2-, genomic low risk BC benefited from chemotherapy with improved long-term outcomes, whereas low risk postmenopausal women did not. Here, ERBB2 is linked to breast cancer.